Victoria Johnson

Reporting on cell and gene therapies for @CGT_Live 🧬| @Rutgersnb Class of 2020 🎓 [email protected] 📧 | Tweets my own ✍️ 🇵🇭

Articles

Systemic Symptoms of PR-10-Related Pollen Food Allergy Syndrome High in Pediatric Patients Surveyed

4 days ago | hcplive.com | Victoria Johnson

New research has highlighted the prevalence of systemic symptoms associated with PR-10 pollen food allergy syndrome (PFAS) in pediatric patients.1PFAS is generally recognized as a mild condition associated with oral allergy syndrome (OAS), but it is increasingly understood to be a condition that can cause systemic symptoms.
COVID-19 Vaccination Protects Against New-Onset, Post-Infection Fibromyalgia

6 days ago | hcplive.com | Victoria Johnson

Author(s):Fact checked by: COVID-19 vaccination is associated with a reduced risk of new-onset fibromyalgia in COVID-19 survivors, as shown by Kaplan–Meier survival analysis. Subgroup analyses reveal protective effects of vaccination against FM in males, individuals with BMI <30, and those with depression or anxiety.
Global Rates of Gout Rising in Young Adults

6 days ago | hcplive.com | Victoria Johnson

Rates of adolescent gout are increasing worldwide, representing an escalating global health issue, and early intervention is needed to reduce disease burden, according to a new study.1“Gout increasingly affects adolescents. However, comprehensive data on adolescent gout are scarce.
Aquatic Exercise, Resistance Training Most Beneficial for Reducing Fibromyalgia Pain

1 week ago | hcplive.com | Victoria Johnson

Aquatic exercise for the short term, and then resistance training for the long term, were the most effective therapeutic exercises (TE) for reducing pain intensity in women with fibromyalgia, according to a new network meta-analysis (NMA).1“To date, we have not found any publications that compares all TE approaches with each other for the treatment of pain in fibromyalgia.
Shared Decision-Making Needed to Address Environmental, Social Factors of Asthma Management

1 week ago | hcplive.com | Victoria Johnson

A shared decision-making approach for dialogue with patients with asthma and their caregivers is needed to best address and manage address the nonpharmacologic aspects of asthma management, including social and environmental factors.1 “Discussions around asthma management tend to focus on the therapeutic aspects… However, there are many other components of asthma management that are now receiving increased attention as we seek to make right on health disparities and strive towards health...
Higher HbA1C Levels Associated With Worse Pediatric Asthma Control

1 week ago | hcplive.com | Victoria Johnson

New research has found that higher HbA1c levels were associated with worse asthma control among children, supporting previous findings that metabolic dysfunction may influence asthma morbidity.1“Insulin receptors have been identified in lung epithelial cells and may play a role in airway hyperresponsiveness, supporting the concept that obesity and asthma could be influenced by metabolic conditions such as diabetes and hyperglycemia.
Virtual Pulmonary Rehabilitation an Accessible Solution for Patients With COPD on Oxygen

1 week ago | hcplive.com | Victoria Johnson

Author(s):Fact checked by: Virtual PR is effective for COPD patients, showing significant improvements in clinical outcomes like CAT scores and mMRC dyspnea scale. The program involved individualized exercise plans, real-time monitoring, and was developed by certified professionals, ensuring safety and feasibility. High program completion rates were observed, with smoking status affecting attendance; adverse events were minimal.
Ustekinumab-aekn Now Interchangeable With Reference for PsA, PsO, CD, UC

1 week ago | hcplive.com | Victoria Johnson

Ustekinumab-aekn (Selarsdi) has received the interchangeable designation with the reference biologic ustekinumab (Stelara), as of April 30, 2025, for treating adults and pediatric with psoriatic arthritis, plaque psoriasis, Crohn disease, and ulcerative colitis.1 "The FDA’s confirmation of full interchangeability for SELARSDI is an important development for patients and providers seeking to expand access to this important treatment," Thomas Rainey, Senior Vice President, U.S. Biosimilars at...
FDA News Recap: April 2025

1 week ago | hcplive.com | Victoria Johnson

Welcome back to our recap of this month's news and updates from the US Food and Drug Administration (FDA)!April 2025 continued the FDA’s momentum in ushering in transformative therapies, with approvals spanning rare diseases, autoimmune disorders, and hematologic conditions. From the first approved therapy for IgG4-related disease to gene therapy for recessive dystrophic epidermolysis bullosa, the month’s decisions reflect a growing focus on targeted, patient-specific treatments.
Pulmonology Month in Review: April 2025

2 weeks ago | hcplive.com | Victoria Johnson

In April, pulmonology research brought forward new evidence supporting advances in care for several chronic and burdensome respiratory conditions. In eosinophilic COPD, a phase 3 trial found that add-on mepolizumab therapy significantly reduced exacerbation rates compared to placebo, pointing to a valuable new option for patients who continue to experience symptoms despite standard treatment.